Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 60 Sep 16 – Oct 15, 2026
- Disclosed funding
- $2.1B 44 disclosed amounts
- Median round
- $16.3M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| BT Breye Therapeutics develops oral medicines for retinal diseases. | €67.5M | Series A | Biotech | Denmark | Investors | |
| MB MOYOM BiotechCompany profile Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments. Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments. | Undisclosed | Financing roundUndisclosed | Biotech, Healthtech | China | Investors | |
| W WonderTxCompany profile AI models designed to discover oral medicines for diseases currently treated with injectable drugs. AI models designed to discover oral medicines for diseases currently treated with injectable drugs. | $125K | Seed | Biotech | United States | Investors | |
| P PilgrimCompany profile Develops autonomous biological-threat detection hardware for defense and critical infrastructure. Develops autonomous biological-threat detection hardware for defense and critical infrastructure. | $25M | Seed | Biotech | United States | Investors | |
| RT Rejuvenation TechnologiesCompany profile Rejuvenation Technologies develops targeted mRNA therapies intended to extend telomeres and restore cellular regenerative capacity in age-related disease. Rejuvenation Technologies develops targeted mRNA therapies intended to extend telomeres and restore cellular regenerative capacity in age-related disease. | Undisclosed | InvestmentUndisclosed | Biotech | United States | Investors | |
| EB Everest BiolabsCompany profile Automated instruments and assays that help biomedical researchers isolate and analyze extracellular vesicles from biological samples. Automated instruments and assays that help biomedical researchers isolate and analyze extracellular vesicles from biological samples. | $2.1M | SBIR Direct-to-Phase II grantUndisclosed | Biotech | United States | Investors | |
| KT Kasvu TherapeuticsCompany profile Kasvu Therapeutics develops small-molecule treatments intended to stimulate neuroplasticity without the hallucinogenic effects associated with psychedelic drugs. Kasvu Therapeutics develops small-molecule treatments intended to stimulate neuroplasticity without the hallucinogenic effects associated with psychedelic drugs. | €30M | Series A | Biotech | Finland | Investors | |
| UI United ImmunityCompany profile A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue. A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue. | ¥2.2B | Private financingUndisclosed | Biotech | Japan | Investors Aozora HYBRID Fund IIIFujita TT Impact Fund I +11ITOCHU CorporationJoyo Bank, Ltd.Kobe University Fund IMitsubishi UFJ Life Sciences Fund IIMiyako Kyoto University Innovation Fund IIIMizuho Life Sciences Fund INVCC Fund 10Ono Venture Investment, Inc.Ricoh Biomedical Startup Investment Limited PartnershipSaisei Bioventures L.P.UTEC Fund V Limited Partnership | |
| BB BigHat BiosciencesCompany profile An AI and synthetic-biology platform that designs and engineers antibody therapeutics. An AI and synthetic-biology platform that designs and engineers antibody therapeutics. | $75M | Series CSeries C+ | Biotech | United States | Investors | |
| E EnginZymeCompany profile EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes. EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes. | SEK 75M | Equity roundUndisclosed | Biotech | Sweden | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Sep 16, 2026
- 1Novo Holdings
OMass Therapeutics, AnaCardio, Breye Therapeutics
3rounds3led - 2Industrifonden
OlsAro, AnaCardio, EnginZyme
3rounds1led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
3rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
3rounds1led - 5Forbion
OMass Therapeutics, Sling Therapeutics, Inc.
2rounds2led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.